Cargando…

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells

Imatinib is actively transported by organic cation transporter-1 (OCT-1) influx transporter, and low OCT-1 activity in diagnostic chronic myeloid leukemia blood mononuclear cells is significantly associated with poor molecular response to imatinib. Herein we report that, in diagnostic chronic myeloi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jueqiong, Lu, Liu, Kok, Chung H., Saunders, Verity A., Goyne, Jarrad M., Dang, Phuong, Leclercq, Tamara M., Hughes, Timothy P., White, Deborah L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477603/ https://www.ncbi.nlm.nih.gov/pubmed/28154092 http://dx.doi.org/10.3324/haematol.2016.153270

Ejemplares similares

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
por: Pagani, Ilaria S., et al.
Publicado: (2018)

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
por: Kok, Chung H., et al.
Publicado: (2023)

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
por: Eadie, Laura N., et al.
Publicado: (2018)

Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells
por: Kumar, Harish, et al.
Publicado: (2020)

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells
por: Wang, J, et al.
Publicado: (2012)

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
por: Lee, Kyeong Won, et al.
Publicado: (2011)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
por: Banjar, Haneen, et al.
Publicado: (2017)

S151: COMBINATION OF LARGE SPLEEN AND LOW IN VIVO KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA
por: Kok, Chung, et al.
Publicado: (2023)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Structural Basis for the Regulation of PPARγ Activity by Imatinib
por: Jang, Jun Young, et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor-γ in Thyroid Autoimmunity
por: Ferrari, Silvia Martina, et al.
Publicado: (2015)

Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation
por: Ohshima, Kousei, et al.
Publicado: (2012)

Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis
por: Liu, Huang-Jun, et al.
Publicado: (2016)

Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases
por: Zhang, Su, et al.
Publicado: (2015)

Effect of peroxisome proliferator-activated receptor γ on inflammatory markers
por: Khazaei, Majid
Publicado: (2015)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro
por: Alexander, Stephen PH, et al.
Publicado: (2012)

Antifibrotic effect by activation of peroxisome proliferator-activated receptor–γ in corneal fibroblasts
por: Pan, Hongwei, et al.
Publicado: (2009)

Peroxisome Proliferator-Activated Receptor γ Activity is Required for Appropriate Cardiomyocyte Differentiation
por: Peymani, Maryam, et al.
Publicado: (2016)

Peroxisome Proliferator‐Activated Receptor‐γ in Capillary Endothelia Promotes Fatty Acid Uptake by Heart During Long‐Term Fasting
por: Goto, Kosaku, et al.
Publicado: (2013)

Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis
por: Żółkiewicz, Jakub, et al.
Publicado: (2019)

Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-γ Ligands in Lung Cancer
por: Nemenoff, Raphael A., et al.
Publicado: (2008)

Sulindac Derivatives That Activate the Peroxisome Proliferator-activated Receptor γ but Lack Cyclooxygenase Inhibition
por: Felts, Andrew S., et al.
Publicado: (2008)

Activation of peroxisome proliferator-activated receptor γ inhibits vascular calcification by upregulating Klotho
por: Cheng, Lijuan, et al.
Publicado: (2017)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
por: Shanmuganathan, Naranie, et al.
Publicado: (2023)

Peroxisome Proliferator–activated Receptors α and γ Down-regulate Allergic Inflammation and Eosinophil Activation
por: Woerly, Gaetane, et al.
Publicado: (2003)

Peroxisome proliferator‐activated receptor gamma (PPARγ) regulates lactase expression and activity in the gut
por: Fumery, Mathurin, et al.
Publicado: (2017)

Assessment of total, ligand-induced peroxisome proliferator activated receptor γ ligand activity in serum
por: Edwards, Lariah, et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor-γ in Amyotrophic Lateral Sclerosis and Huntington's Disease
por: Kiaei, Mahmoud
Publicado: (2008)

The pathophysiological function of peroxisome proliferator-activated receptor-γ in lung-related diseases
por: Huang, Tom Hsun-Wei, et al.
Publicado: (2005)

Peroxisome Proliferator-Activated Receptor-γ-Mediated Polarization of Macrophages in Leishmania Infection
por: Chan, Marion M., et al.
Publicado: (2012)

Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity
por: Corzo, Cesar, et al.
Publicado: (2013)

Functions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic Disorders
por: Ren, Ping, et al.
Publicado: (2015)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands
por: Mottin, Melina, et al.
Publicado: (2016)

Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer
por: Huang, Guodong, et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptor-γ Modulates the Response of Macrophages to Lipopolysaccharide and Glucocorticoids
por: Heming, Michael, et al.
Publicado: (2018)

New Target Genes for the Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Antitumour Activity: Perspectives from the Insulin Receptor
por: Foti, Daniela P., et al.
Publicado: (2009)

Zafirlukast Is a Dual Modulator of Human Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptor γ
por: Göbel, Tamara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2einob69jr61vorufsdcq6jaoq